2024. 05
Caliway Presents CBL-514 Phase 2 Subcutaneous Fat Reduction Study Results Met All the Endpoints Successfully at AMWC Asia-TDAC 2024
New Taipei City, May 24th, 2024—Caliway Biopharmaceuticals (Caliway) is pleased to announce that Dr. Peter Peng, Chair of the Taiwan Society for Dermatology and Aesthetic Surgery, presents the results of the Phase II clinical trial of CBL-514, the first-in-class candidate drug developed by Caliway, for localized fat reduction (NCT04897412) at the 6th World Congress of Aesthetic Medicine Asia (AMWC Asia-TDAC 2024).
Dr. Peng mentioned that CBL-514 is a multi-indication injection for localized fat reduction, cellulite, and the treatment of the rare disease Dercum's disease. In the Phase II clinical study for local fat reduction (Phase II 0202), CBL-514 showed an average reduction in subcutaneous fat of 312mL and was safe and well-tolerated.
About CBL-514
CBL-514, a potentially first-in-class small-molecule drug, is an injection lipolysis drug that can induce adipocyte apoptosis and lipolysis to reduce subcutaneous adiposity in treatment areas in animal studies without causing any systematic side effects on the central nervous system, cardiovascular system, and respiratory system. Caliway’s nonclinical studies showed that CBL-514 upregulates the apoptosis mediators caspase 3 and Bax/Bcl-2 ratio, and then induces dose-dependent adipocyte apoptosis in vivo and in vitro.
Caliway is investigating multiple indications for CBL-514, including noninvasive subcutaneous fat reduction, Dercum’s disease and cellulite, which has successfully met the primary and secondary endpoints of three clinical trials.
About AMWC Asia
The Aesthetic & Anti-Aging Medicine World Congress (AMWC) is one of the world's most important and prestigious medical conferences in the field of aesthetics. It is attended by 15,000 healthcare professionals from all over the world each year and organizes a series of conferences in key regions of the world. AMWC Asia in Taipei is one of the world’s leading medical science series on aesthetics and anti-aging, organized by IM-Aesthetics and the Taiwan Dermatology Association.
About Caliway Biopharmaceuticals
Caliway Biopharmaceuticals (Caliway) is a Taiwan-headquartered, clinical-stage biopharmaceutical company driven to breakthrough drug discovery of novel small-molecule therapeutics. Listed on the emerging stock market in Taiwan (TPEX6919), Caliway aims to become an innovative pharmaceutical leader in aesthetic medicine and inflammatory disease.
Disclaimer
This article and related information on this site contain forward-looking statements. The forward-looking information requires the Company to make numerous assumptions and is subject to inherent risks, uncertainties, and other factors that are beyond the control of the Company which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. The Company undertakes no obligation to timely inform, update, or revise the information on this site if circumstances should change.
Dr. Peng mentioned that CBL-514 is a multi-indication injection for localized fat reduction, cellulite, and the treatment of the rare disease Dercum's disease. In the Phase II clinical study for local fat reduction (Phase II 0202), CBL-514 showed an average reduction in subcutaneous fat of 312mL and was safe and well-tolerated.
About CBL-514
CBL-514, a potentially first-in-class small-molecule drug, is an injection lipolysis drug that can induce adipocyte apoptosis and lipolysis to reduce subcutaneous adiposity in treatment areas in animal studies without causing any systematic side effects on the central nervous system, cardiovascular system, and respiratory system. Caliway’s nonclinical studies showed that CBL-514 upregulates the apoptosis mediators caspase 3 and Bax/Bcl-2 ratio, and then induces dose-dependent adipocyte apoptosis in vivo and in vitro.
Caliway is investigating multiple indications for CBL-514, including noninvasive subcutaneous fat reduction, Dercum’s disease and cellulite, which has successfully met the primary and secondary endpoints of three clinical trials.
About AMWC Asia
The Aesthetic & Anti-Aging Medicine World Congress (AMWC) is one of the world's most important and prestigious medical conferences in the field of aesthetics. It is attended by 15,000 healthcare professionals from all over the world each year and organizes a series of conferences in key regions of the world. AMWC Asia in Taipei is one of the world’s leading medical science series on aesthetics and anti-aging, organized by IM-Aesthetics and the Taiwan Dermatology Association.
- Time：May 24-26,2024
- Location：Taipei International Convention Center (TICC)，1 Hsin-Yi Road, Section 5, Hsin-Yi District, Taipei City, Taiwan
- Website：AMWC Asia-TDAC - Taipei's Aesthetic Medicine World Congress
About Caliway Biopharmaceuticals
Caliway Biopharmaceuticals (Caliway) is a Taiwan-headquartered, clinical-stage biopharmaceutical company driven to breakthrough drug discovery of novel small-molecule therapeutics. Listed on the emerging stock market in Taiwan (TPEX6919), Caliway aims to become an innovative pharmaceutical leader in aesthetic medicine and inflammatory disease.
Disclaimer
This article and related information on this site contain forward-looking statements. The forward-looking information requires the Company to make numerous assumptions and is subject to inherent risks, uncertainties, and other factors that are beyond the control of the Company which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. The Company undertakes no obligation to timely inform, update, or revise the information on this site if circumstances should change.